Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have been given an average recommendation of “Buy” by the twelve brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $23.78.

SNDX has been the topic of several research analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $25.00 price objective (up previously from $24.00) on shares of Syndax Pharmaceuticals in a report on Monday, July 10th. Zacks Investment Research downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Citigroup Inc. set a $20.00 price objective on Syndax Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 11th. Nomura cut their price objective on Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 11th. Finally, Oppenheimer Holdings, Inc. boosted their price objective on Syndax Pharmaceuticals to $29.00 and gave the company an “outperform” rating in a report on Friday, August 11th.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System increased its holdings in Syndax Pharmaceuticals by 60.9% during the 2nd quarter. California State Teachers Retirement System now owns 15,587 shares of the company’s stock worth $218,000 after purchasing an additional 5,900 shares during the period. TIAA CREF Investment Management LLC increased its holdings in Syndax Pharmaceuticals by 36.2% during the 1st quarter. TIAA CREF Investment Management LLC now owns 22,924 shares of the company’s stock worth $315,000 after purchasing an additional 6,091 shares during the period. New York State Common Retirement Fund increased its holdings in Syndax Pharmaceuticals by 421.9% during the 2nd quarter. New York State Common Retirement Fund now owns 9,400 shares of the company’s stock worth $131,000 after purchasing an additional 7,599 shares during the period. Teachers Advisors LLC increased its holdings in Syndax Pharmaceuticals by 109.9% during the 2nd quarter. Teachers Advisors LLC now owns 15,451 shares of the company’s stock worth $216,000 after purchasing an additional 8,091 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Syndax Pharmaceuticals by 43.5% during the 1st quarter. Bank of New York Mellon Corp now owns 29,227 shares of the company’s stock worth $401,000 after purchasing an additional 8,861 shares during the period. Institutional investors own 70.68% of the company’s stock.

Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 11.90 on Friday. The stock’s 50 day moving average price is $11.86 and its 200 day moving average price is $11.84. Syndax Pharmaceuticals has a 52 week low of $6.31 and a 52 week high of $16.40. The stock’s market cap is $264.41 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.09. The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.31 million. Syndax Pharmaceuticals had a negative return on equity of 58.23% and a negative net margin of 4,294.59%. On average, analysts forecast that Syndax Pharmaceuticals will post ($3.11) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Syndax Pharmaceuticals, Inc. (SNDX) Given Average Recommendation of “Buy” by Brokerages” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/09/16/syndax-pharmaceuticals-inc-sndx-given-average-recommendation-of-buy-by-brokerages.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.